Adalta Ltd. · ASX:1AD
Adalta — Shareholder Meeting (November 2024)
31 slides from Adalta's shareholder meeting presentation, Nov 20, 2024
Slide 1: ASX Announcement: AGM presentations
ASX Announcement/Press Release | 20 November 2024 AdAlta Limited (ASX:1AD) AGM presentations MELBOURNE Australia, 20 November 2024: AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), the clinical stage drug discovery company developing novel protein and cell therapeutic products from its i-body®
Slide 2: For more information
CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development. AdAlta’s strategy is to maximis
Slide 3: Chair's address – AdAlta Annual General Meeting 2024
Chair’s address – AdAlta Annual General Meeting 2024 Ladies and gentlemen, Welcome to AdAlta’s 2024 Annual General Meeting. Our purpose is to go where traditional antibody and small molecule drugs cannot, developing next generation protein and cell therapeutic products to address otherwise fatal dis
Slide 4: Chair's address (continued): adapting to the funding environment
The recovery in biotech financing is being supported by record levels of capital raised by VC funds in 2023 that now needs to be deployed. And AdAlta has taken deliberate and considered steps to adapt to the current environment including: • establishing AdSolis to enable direct, third party investme
Slide 5: Chair's address (continued): AdCella
own immune cells to fight cancer and other diseases. Cellular immunotherapies have transformed outcomes for blood cancer patients, and with the first approvals of these products now emerging in solid cancers, a ten times larger market. We can be at the cutting edge of this revolution. AdCella has be
Slide 6: Chair's address (continued): thanks and Board changes
2. Our staff who, despite the macro-economic challenges, remain extremely focused on delivering new therapeutics to patients who desperately need them. They have all embraced new roles and tasks as we increase our focus on AdSolis, AdCella and transactions 3. Our expanded advisory panel who bring de
Slide 7: Building our clinical pipeline – CEO presentation to AGM
For personal use only Building our clinical pipeline AdAlta Limited (ASX:1AD) A modern targeting system for next generation drugs CEO presentation to AGM November 2024
Slide 8: Disclaimer
Disclaimer Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. For personal use only This presentation is not an offer or in
Slide 9: AdAlta is on a transformation journey
AdAlta is on a transformation journey Building a substantial and For personal use only sustainable company ▪ Multiple clinical stage assets 2025 and beyond ▪ Regular news flow – value inflections every 4-6 2023 months • 2 clinical trials completed 2021 • 1 clinical stage program • AdSolis, AdCella b
Slide 10: 2024 – significant progress on our transformation journey
2024 – significant progress on our transformation journey 2024 achievements ▪ Completed second Phase I clinical trial of AD-214 supporting For personal use only 1. AdSolis: a new approach to fibrotic disease safety of likely efficacious dose ▪ Developed dosimetry model – supports market preferred SC
Slide 11: Headwinds are dropping, tailwinds returning to the sector
Headwinds are dropping, tailwinds returning to the sector For personal use only Source: Jonathan Norris, HSBC Venture Healthcare Report 1H 2024 (https://www.business.us.hsbc.com/en/campaigns/innovation-banking/venture-healthcare-report) and Livewire Markets * November 2024 (https://www.livewiremarke
Slide 12: Near-term momentum and opportunities for shareholders
Near-term momentum and opportunities for shareholders For personal use only Attractive current valuation and fundamentals Share price performance (ASX:1AD) (12 months) 0.04 16.0 0.03 12.0 Share price (A$) Volume (m) Momentum building towards return on AD-214 investment - 0.02 8.0 AdSolis 0.01 4.0 0.
Slide 13: AdAlta: unique discovery platform, expanding business model
AdAlta (ASX:1AD): unique discovery platform, expanding business model For personal use only A new approach to fibrotic disease Larger biopharma companies Out-licensing and co-development Next generation protein and cell therapeutics AdCella East to west cellular immunotherapies Discovery business Pr
Slide 14: AD-214: new hope for fibrotic disease patients
For personal use only AD-214: new hope for fibrotic disease patients
Slide 15: The need: fibrotic diseases including IPF have no good outcomes today
7 The need: fibrotic diseases including Idiopathic Pulmonary Fibrosis (IPF) have no good outcomes today IPF market is underserved today Current IPF treatments Many other fibrosis market opportunities • Two existing therapies generated US$4.3b in 2022 Every organ vulnerable: • They slow but do not ha
Slide 16: The solution: AD-214 momentum and development strategy
11 The solution: AD-214 momentum and development strategy A$45m investment to date has built strong value proposition Product development priorities Progress and momentum First in class molecule targeting established mode of action in For personal use only fibrotic disease 1. Generate clinical proof
Slide 17: AD-214 offers a competitive and differentiated product profile
8 AD-214 offers a competitive and differentiated product profile compared with leading disease modifying candidates 1 Product Attributes AD-214 BI-1015550 BMS-986278 Bexotegrast For personal use only Sponsor AD-214 difference: Development stage Phase I/II Phase III Phase III Phase II/III • Novel mod
Slide 18: The value: Pharma companies are actively licensing IPF assets
13 The value: Pharma companies are actively licensing IPF assets for significant value Upfront payment to Clinical Phase at Date Licensor/target Licensee/acquirer Transaction Contingent milestones licensor^^ transaction For personal use only Aug-22 License US$100m US$600m 2 complete Apr-20 Acquisiti
Slide 19: The global advisory team: Experienced team to execute
9 The global advisory team: Experienced team to execute CONSULTANTS CLINICAL ADVISORY BOARD 1 Prof Tamera Corte Prof Toby Maher Royal Prince Alfred Hospital Keck School of Medicine CONSULTANT CHIEF MEDICAL OFFICER University of Sydney USC For personal use only 30y pulmonary clinical practice 20y res
Slide 20: AdCella: AdAlta's 'east to west' cellular immunotherapy strategy
AdCella For personal use only AdAlta’s “east to west” cellular immunotherapy strategy
Slide 21: Cellular immunotherapies are transforming cancer outcomes
Cellular immunotherapies are transforming cancer outcomes New, multifunctional therapies are needed to address solid cancers Therapy involves re-engineering patient’s own immune cells to “see” cancer – living drug, single dose, potentially curative For personal use only 6 FDA-approved CAR-T therapie
Slide 22: AdCella business model: force multiplier for Asian partners
AdCella business model: force multiplier for Asian partners For personal use only 1. In-license market leading assets from Asia 3. Establish global manufacturing network and on-license to commercialization partners World class advanced therapies clinical trial and translational research AdCella Prod
Slide 23: Strong and experienced management team available to AdCella
Strong and experienced management team available to AdCella Tim Oldham, PhD David Fuller, MD Kevin Lynch, MD CEO & MANAGING NON-EXECUTIVE DIRECTOR – CHIEF MEDICAL OFFICER – ADCELLA DIRECTOR Clinical Advisor For personal use only • 25 years industry physician experience across • 10 years cell and gen
Slide 24: Asset selection criteria
Asset selection criteria For personal use only ❑ Solid cancer indication – no hyper competitive blood cancer indications ❑ Target validated by clinical development programs in cell therapy or other modalities – reduces target risk ❑ US FDA IND ready – amend to add AdCella’s preferred CDMO; some asse
Slide 25: Deal comparators at AdCella exit: Phase I CAR-T transactions
Deal comparators at AdCella exit: Phase I CAR-T cell therapy transactions Total value Upfront Date Drug(s) Licensor Licensee Deal stage Lead indications (US$m) (US$m) For personal use only DLL3 targeting Phase 1 Nov-23 autologous CAR-T cell Legend Biotech Novartis SCLC, LCNEC 1110 100 (ongoing; US)
Slide 26: Why invest in AdCella
Why invest in AdCella - a future powerhouse in cellular immunotherapy Large, rapidly growing market for cellular immunotherapies for solid cancers For personal use only Unique business model enables low cost asset acquisition: AdCella ”buys in” by allocating capital to develop assets and sharing ups
Slide 27: Unlocking value in i-body pipeline
For personal use only Unlocking value in i-body pipeline
Slide 28: Near term milestones and objectives
Near term milestones and objectives Near term milestones ▪ Out-licensing or co-development/asset financing to provide For personal use only 1. AdSolis: a new approach to fibrotic disease capital for further development of AD-214, crystalize the value of AD-214 to AdAlta Multiple term sheets being ne
Slide 29: Independent Non-Executive Director changes
Independent Non-Executive Director changes ROBERT PEACH RETIRES MICHELLE BURKE TO JOIN IAIN ROSS TO JOIN For personal use only 23
Slide 30: AdAlta's foundations in place for transaction driven growth
AdAlta’s foundations in place for transaction driven growth AdSolis: Lead asset AD-214 heading to Phase II (US$4.3b IPF market plus other indications), substantially de-risked by Phase I extension study clinical readouts For personal use only AdSolis: AD-214 partnering window open with multiple opti
Slide 31: A modern targeting system for next generation drugs
A modern targeting system for next generation drugs For personal use only AdAlta Ltd (ASX:1AD) AGM Presentation November 2024 For more information please contact: Tim Oldham CEO & Managing Director +61 403 446 665 [email protected] Investor Relations The Capital Network Julia Maguire +61 2 7257